PRAGUE MEDICAL REPORT, Vol 120 No 2 (2019), 52–63
Pharmacokinetics of Dasatinib
Jana Hořínková, Martin Šíma, Ondřej Slanař
DOI: https://doi.org/10.14712/23362936.2019.10
zveřejněno: 07. 10. 2019
Abstract
Tyrosine kinase inhibitors have recently become an essential tool in management of chronic myeloid leukaemia (CML). Dasatinib, a representative of those drugs, acts by inhibiting key proteins included in CML development, predominantly Bcr-Abl and Src. Its advantage is that it shows activity in many cases where other agents bring no improvement due to resistance. Pharmacokinetics of dasatinib has specific characteristics that may play an important role in achieving sufficient exposure in patients. Therefore, the key pharmacokinetic properties are summarized in this report. For example, dasatinib absorption is significantly influenced by gastric pH and its modulation can be a source of serious interactions, as well as simultaneous administration of drugs affecting cytochrome P450.
klíčová slova: Dasatinib; Pharmacokinetics; pH-dependent absorption; Drug interaction
Pharmacokinetics of Dasatinib is licensed under a Creative Commons Attribution 4.0 International License.
167 x 240 mm
vychází: 4 x ročně
cena tištěného čísla: 450 Kč
ISSN: 1214-6994
E-ISSN: 2336-2936